Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05974852 · ClinicalTrials.gov registry record
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 732
- Enrollment target
NCT05974852 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 732 participants.
The verdict
NCT05974852 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 732 participants
- Enrollment target
Study Summary
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
Interventions
- OTHER Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2023-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05974852
The ClinicalTrials.gov registry entry for NCT05974852 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT05974852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05974852 about?
NCT05974852 is a clinical study titled "Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS". The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
What is the current status of trial NCT05974852?
This trial is currently completed. The enrollment target is 732 participants. The study started on 2023-10-01. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT05974852?
The interventions under investigation include: Ocrelizumab (OTHER).
Who is sponsoring clinical trial NCT05974852?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.